Skip Navigation

Coronavirus (COVID-19) information for Dana-Farber patients & families Learn more

Mary-Ellen Taplin, MD


Medical Oncology

Make an Appointment
Watch Video

Physician

  • Chair, Executive Committee for Clinical Research
  • Director of Clinical Research, Lank Center for Genitourinary Oncology
  • Institute Physician
  • Professor of Medicine, Harvard Medical School

Centers/Programs

Clinical Interests

  • Bladder cancer
  • Clinical trials
  • Hormone and chemotherapy
  • Kidney cancer
  • Prostate cancer
  • Testis cancer

Diseases Treated

Contact Information

  • Appointments877-332-4294 (new)
    617-582-9725 (follow-up)
  • Office Phone Number617-582-7221
  • Fax617-632-2165

Bio

Dr. Taplin received her MD in 1986 from the University of Massachusetts, Worcester. She completed a residency in internal medicine and chief residency at the University of Massachusetts Medical Center and an oncology-hematology fellowship at Beth Israel Hospital and Harvard Medical School. Dr. Taplin was on staff in medical oncology-hematology as an assistant and then associate professor of medicine at the University of Massachusetts from 1993 to 2003, when she joined Dana-Farber Cancer Institute.

Board Certification:

  • Hematology, 1996
  • Internal Medicine, 1989
  • Medical Oncology, 1993

Fellowship:

  • Beth Israel Deaconess Medical Center, Hematology/Oncology

Residency:

  • University of Massachusetts Medical Center, Chief Medical Resident
  • University of Massachusetts Medical Center, Internal Medicine

Medical School:

  • University of Massachusetts Medical School

Recent Awards:

  • Dana-Farber Cancer Center Medical Oncology Teaching Award 2009

Research

Since completing her Hematology-Oncology fellowship at Beth Israel Medical Center/Harvard Medical School in 1993, Dr. Mary-Ellen Taplin has dedicated herself to academic genitourinary (GU) oncology at the University of Massachusetts Medical Center (1993-2003) and Dana-Farber Cancer Institute (DFCI)/Harvard Medical School (2003-present). Dr. Taplin has assiduously focused on clinical and correlative investigations in prostate cancer while providing outstanding patient care, teaching and mentoring trainees and developing excellent administrative skills in clinical research management. She is a key opinion leader in GU oncology and has provided leadership in all phases of clinical trials. She was the principal investigator for the first biomarker (androgen receptor splice variant) directed trial (galeterone) in metastatic prostate cancer. Leadership on the phase 3 galeterone trial and her work with abiraterone and enzalutamide demonstrates the full circle of bench to bedside, as Dr. Taplin was the first to report androgen receptor mutations in metastatic prostate cancer samples in the New England Journal of Medicine in 1995. Her work has increased the understanding of mechanisms of prostate cancer response and resistance and remains important especially in the context of next generation hormone therapy in prostate cancer. Dr. Taplin’s dedication, clinical expertise and service together with her innovation and publication record supported her promotion to Professor of Medicine at Harvard Medical School in 2017.


 

Prospective Evaluation of Clinical Outcomes Using a Multiplex Liquid Biopsy Targeting Diverse Resistance Mechanisms in Metastatic Prostate Cancer. J Clin Oncol. 2021 Jul 01; JCO2100169.
View in: PubMed

Impact of Pathogenic Germline DNA Damage Repair alterations on Response to Intense Neoadjuvant Androgen Deprivation Therapy in High-risk Localized Prostate Cancer. Eur Urol. 2021 Apr 19.
View in: PubMed

Phase II Multicenter Study of Enzalutamide in Metastatic Castration-Resistant Prostate Cancer to Identify Mechanisms Driving Resistance. Clin Cancer Res. 2021 Jul 01; 27(13):3610-3619.
View in: PubMed

Results of a Randomized Phase II Trial of Intense Androgen Deprivation Therapy prior to Radical Prostatectomy in Men with High-Risk Localized Prostate Cancer. J Urol. 2021 07; 206(1):80-87.
View in: PubMed

Transcriptional mediators of treatment resistance in lethal prostate cancer. Nat Med. 2021 03; 27(3):426-433.
View in: PubMed

Enzalutamide With Radiation Therapy for Intermediate-Risk Prostate Cancer: A Phase 2 Study. Int J Radiat Oncol Biol Phys. 2021 Aug 01; 110(5):1416-1422.
View in: PubMed

Outcomes of Post-Neoadjuvant Intense Hormone Therapy and Surgery for High Risk Localized Prostate Cancer: Results of a Pooled Analysis of Contemporary Clinical Trials. J Urol. 2021 06; 205(6):1689-1697.
View in: PubMed

Initial Management of Noncastrate Advanced, Recurrent, or Metastatic Prostate Cancer: ASCO Guideline Update. J Clin Oncol. 2021 Apr 10; 39(11):1274-1305.
View in: PubMed

Identification of a Synthetic Lethal Relationship between Nucleotide Excision Repair Deficiency and Irofulven Sensitivity in Urothelial Cancer. Clin Cancer Res. 2021 Apr 01; 27(7):2011-2022.
View in: PubMed

Practical Considerations and Challenges for Germline Genetic Testing in Patients With Prostate Cancer: Recommendations From the Germline Genetics Working Group of the PCCTC. JCO Oncol Pract. 2020 12; 16(12):811-819.
View in: PubMed

The Impact of COVID-19 on Clinical Trial Execution at the Dana-Farber Cancer Institute. J Natl Cancer Inst. 2020 Sep 22.
View in: PubMed

Dual Blockade of c-MET and the Androgen Receptor in Metastatic Castration-resistant Prostate Cancer: A Phase I Study of Concurrent Enzalutamide and Crizotinib. Clin Cancer Res. 2020 12 01; 26(23):6122-6131.
View in: PubMed

Genomic Predictors of Good Outcome, Recurrence, or Progression in High-Grade T1 Non-Muscle-Invasive Bladder Cancer. Cancer Res. 2020 10 15; 80(20):4476-4486.
View in: PubMed

Treatment of metastatic castration resistant prostate cancer with radium-223: a retrospective study at a US tertiary oncology center. Prostate Cancer Prostatic Dis. 2021 03; 24(1):210-219.
View in: PubMed

Cancer and Leukemia Group B 90203 (Alliance): Radical Prostatectomy With or Without Neoadjuvant Chemohormonal Therapy in Localized, High-Risk Prostate Cancer. J Clin Oncol. 2020 09 10; 38(26):3042-3050.
View in: PubMed

Tumor Microenvironment-Derived NRG1 Promotes Antiandrogen Resistance in Prostate Cancer. Cancer Cell. 2020 08 10; 38(2):279-296.e9.
View in: PubMed

Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019. J Clin Oncol. 2020 08 20; 38(24):2798-2811.
View in: PubMed

Volume of Gleason pattern 4 stratifies risk of metastasis and death in patients with Gleason score 3+5=8/5+3=8 positive prostate core biopsies. Hum Pathol. 2020 05; 99:62-74.
View in: PubMed

Methylation of SRD5A2 promoter predicts a better outcome for castration-resistant prostate cancer patients undergoing androgen deprivation therapy. PLoS One. 2020; 15(3):e0229754.
View in: PubMed

Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019. Eur Urol. 2020 04; 77(4):508-547.
View in: PubMed

Multiparametric MRI as a Biomarker of Response to Neoadjuvant Therapy for Localized Prostate Cancer-A Pilot Study. Acad Radiol. 2020 10; 27(10):1432-1439.
View in: PubMed

Androgens and Overall Survival in Patients With Metastatic Castration-resistant Prostate Cancer Treated With Docetaxel. Clin Genitourin Cancer. 2020 06; 18(3):222-229.e2.
View in: PubMed

Androgen Receptor Modulation Optimized for Response-Splice Variant: A Phase 3, Randomized Trial of Galeterone Versus Enzalutamide in Androgen Receptor Splice Variant-7-expressing Metastatic Castration-resistant Prostate Cancer. Eur Urol. 2019 12; 76(6):843-851.
View in: PubMed

Publisher Correction: The long tail of oncogenic drivers in prostate cancer. Nat Genet. 2019 Jul; 51(7):1194.
View in: PubMed

Genomic correlates of clinical outcome in advanced prostate cancer. Proc Natl Acad Sci U S A. 2019 06 04; 116(23):11428-11436.
View in: PubMed

Androgen decline and survival during docetaxel therapy in metastatic castration resistant prostate cancer (mCRPC). Prostate Cancer Prostatic Dis. 2020 03; 23(1):66-73.
View in: PubMed

Evaluating a Video-Based, Personalized Webpage in Genitourinary Oncology Clinical Trials: A Phase 2 Randomized Trial. J Med Internet Res. 2019 05 02; 21(5):e12044.
View in: PubMed

Germline Genetic Testing in Advanced Prostate Cancer; Practices and Barriers: Survey Results from the Germline Genetics Working Group of the Prostate Cancer Clinical Trials Consortium. Clin Genitourin Cancer. 2019 08; 17(4):275-282.e1.
View in: PubMed

Correction: Epigenetic Therapy with Panobinostat Combined with Bicalutamide Rechallenge in Castration-Resistant Prostate Cancer. Clin Cancer Res. 2019 Apr 15; 25(8):2672.
View in: PubMed

Association of prostate cancer SLCO gene expression with Gleason grade and alterations following androgen deprivation therapy. Prostate Cancer Prostatic Dis. 2019 12; 22(4):560-568.
View in: PubMed

Evaluation of Intense Androgen Deprivation Before Prostatectomy: A Randomized Phase II Trial of Enzalutamide and Leuprolide With or Without Abiraterone. J Clin Oncol. 2019 04 10; 37(11):923-931.
View in: PubMed

Impact of new systemic therapies on overall survival of patients with metastatic castration-resistant prostate cancer in a hospital-based registry. Prostate Cancer Prostatic Dis. 2019 09; 22(3):420-427.
View in: PubMed

Prostate Cancer-Specific Mortality Across Gleason Scores in Black vs Nonblack Men. JAMA. 2018 12 18; 320(23):2479-2481.
View in: PubMed

A phase 2 trial of abiraterone acetate without glucocorticoids for men with metastatic castration-resistant prostate cancer. Cancer. 2019 02 15; 125(4):524-532.
View in: PubMed

Tumor fraction in cell-free DNA as a biomarker in prostate cancer. JCI Insight. 2018 11 02; 3(21).
View in: PubMed

Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer. J Clin Invest. 2018 11 01; 128(11):5185.
View in: PubMed

Mechanisms responsible for reduced erythropoiesis during androgen deprivation therapy in men with prostate cancer. Am J Physiol Endocrinol Metab. 2018 12 01; 315(6):E1185-E1193.
View in: PubMed

Systematic Review of Systemic Therapies and Therapeutic Combinations with Local Treatments for High-risk Localized Prostate Cancer. Eur Urol. 2019 01; 75(1):44-60.
View in: PubMed

Downregulation of Dipeptidyl Peptidase 4 Accelerates Progression to Castration-Resistant Prostate Cancer. Cancer Res. 2018 11 15; 78(22):6354-6362.
View in: PubMed

Epigenetic Therapy with Panobinostat Combined with Bicalutamide Rechallenge in Castration-Resistant Prostate Cancer. Clin Cancer Res. 2019 01 01; 25(1):52-63.
View in: PubMed

Phosphorylation of androgen receptor serine 81 is associated with its reactivation in castration-resistant prostate cancer. Cancer Lett. 2018 12 01; 438:97-104.
View in: PubMed

Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer. J Clin Invest. 2018 10 01; 128(10):4441-4453.
View in: PubMed

Evolving Intersection Between Inherited Cancer Genetics and Therapeutic Clinical Trials in Prostate Cancer: A White Paper From the Germline Genetics Working Group of the Prostate Cancer Clinical Trials Consortium. JCO Precis Oncol. 2018; 2018.
View in: PubMed

Abiraterone Alone or in Combination With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer With Rising Prostate-Specific Antigen During Enzalutamide Treatment. J Clin Oncol. 2018 09 01; 36(25):2639-2646.
View in: PubMed

Neoadjuvant-Intensive Androgen Deprivation Therapy Selects for Prostate Tumor Foci with Diverse Subclonal Oncogenic Alterations. Cancer Res. 2018 08 15; 78(16):4716-4730.
View in: PubMed

Structural Alterations Driving Castration-Resistant Prostate Cancer Revealed by Linked-Read Genome Sequencing. Cell. 2018 07 12; 174(2):433-447.e19.
View in: PubMed

A dose finding clinical trial of cabozantinib (XL184) administered in combination with abiraterone acetate in metastatic castration-resistant prostate cancer. Prostate. 2018 Jun 07.
View in: PubMed

Metastatic Castration-Sensitive Prostate Cancer: Optimizing Patient Selection and Treatment. Am Soc Clin Oncol Educ Book. 2018 May 23; 38:363-371.
View in: PubMed

Time of metastatic disease presentation and volume of disease are prognostic for metastatic hormone sensitive prostate cancer (mHSPC). Prostate. 2018 09; 78(12):889-895.
View in: PubMed

Androgen Deprivation Therapy Is Associated With Prolongation of QTc Interval in Men With Prostate Cancer. J Endocr Soc. 2018 May 01; 2(5):485-496.
View in: PubMed

The IMAAGEN Study: Effect of Abiraterone Acetate and Prednisone on Prostate Specific Antigen and Radiographic Disease Progression in Patients with Nonmetastatic Castration Resistant Prostate Cancer. J Urol. 2018 08; 200(2):344-352.
View in: PubMed

The long tail of oncogenic drivers in prostate cancer. Nat Genet. 2018 05; 50(5):645-651.
View in: PubMed

Clinical and Genomic Characterization of Low-Prostate-specific Antigen, High-grade Prostate Cancer. Eur Urol. 2018 08; 74(2):146-154.
View in: PubMed

Clinically Localized Prostate Cancer: AUA/ASTRO/SUO Guideline. Part II: Recommended Approaches and Details of Specific Care Options. J Urol. 2018 04; 199(4):990-997.
View in: PubMed

Clinical Outcomes of First-line Abiraterone Acetate or Enzalutamide for Metastatic Castration-resistant Prostate Cancer After Androgen Deprivation Therapy + Docetaxel or ADT Alone for Metastatic Hormone-sensitive Prostate Cancer. Clin Genitourin Cancer. 2018 04; 16(2):130-134.
View in: PubMed

Post prostatectomy outcomes of patients with high-risk prostate cancer treated with neoadjuvant androgen blockade. Prostate Cancer Prostatic Dis. 2018 09; 21(3):364-372.
View in: PubMed

Clinically Localized Prostate Cancer: AUA/ASTRO/SUO Guideline. Part I: Risk Stratification, Shared Decision Making, and Care Options. J Urol. 2018 03; 199(3):683-690.
View in: PubMed

Genomic Resistance Patterns to Second-Generation Androgen Blockade in Paired Tumor Biopsies of Metastatic Castration-Resistant Prostate Cancer. JCO Precis Oncol. 2017; 1.
View in: PubMed

Muscadine Grape Skin Extract (MPX) in Men with Biochemically Recurrent Prostate Cancer: A Randomized, Multicenter, Placebo-Controlled Clinical Trial. Clin Cancer Res. 2018 01 15; 24(2):306-315.
View in: PubMed

Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors. Nat Commun. 2017 11 06; 8(1):1324.
View in: PubMed

Effects of Androgen Deprivation Therapy on Pain Perception, Quality of Life, and Depression in Men With Prostate Cancer. J Pain Symptom Manage. 2018 02; 55(2):307-317.e1.
View in: PubMed

Expression of PD-L1 in Hormone-naïve and Treated Prostate Cancer Patients Receiving Neoadjuvant Abiraterone Acetate plus Prednisone and Leuprolide. Clin Cancer Res. 2017 Nov 15; 23(22):6812-6822.
View in: PubMed

Impact of Therapy on Genomics and Transcriptomics in High-Risk Prostate Cancer Treated with Neoadjuvant Docetaxel and Androgen Deprivation Therapy. Clin Cancer Res. 2017 Nov 15; 23(22):6802-6811.
View in: PubMed

The impact of statin use on the efficacy of abiraterone acetate in patients with castration-resistant prostate cancer. Prostate. 2017 May; 77(13):1303-1311.
View in: PubMed

Clinical Outcomes of Chemotherapy Naïve Men with Metastatic Castration Resistant Prostate Cancer and Low Baseline Prostate Specific Antigen Treated with Enzalutamide vs Placebo. J Urol. 2017 12; 198(6):1324-1332.
View in: PubMed

Testicular vs adrenal sources of hydroxy-androgens in prostate cancer. Endocr Relat Cancer. 2017 08; 24(8):393-404.
View in: PubMed

Second-Line Hormonal Therapy for Men With Chemotherapy-Naïve, Castration-Resistant Prostate Cancer: American Society of Clinical Oncology Provisional Clinical Opinion. J Clin Oncol. 2017 Jun 10; 35(17):1952-1964.
View in: PubMed

Association of Tissue Abiraterone Levels and SLCO Genotype with Intraprostatic Steroids and Pathologic Response in Men with High-Risk Localized Prostate Cancer. Clin Cancer Res. 2017 Aug 15; 23(16):4592-4601.
View in: PubMed

Aberrant corticosteroid metabolism in tumor cells enables GR takeover in enzalutamide resistant prostate cancer. Elife. 2017 02 13; 6.
View in: PubMed

Neoadjuvant Enzalutamide Prior to Prostatectomy. Clin Cancer Res. 2017 May 01; 23(9):2169-2176.
View in: PubMed

Prostate cancer: Developing novel approaches to castration-sensitive disease. Cancer. 2017 Jan 01; 123(1):29-42.
View in: PubMed

Efficacy of Therapies After Galeterone in Patients With Castration-resistant Prostate Cancer. Clin Genitourin Cancer. 2017 08; 15(4):463-471.
View in: PubMed

A Phase II Trial of Abiraterone Combined with Dutasteride for Men with Metastatic Castration-Resistant Prostate Cancer. Clin Cancer Res. 2017 Feb 15; 23(4):935-945.
View in: PubMed

Radium-223 Use in Clinical Practice and Variables Associated With Completion of Therapy. Clin Genitourin Cancer. 2017 04; 15(2):e289-e298.
View in: PubMed

Predictors of duration of abiraterone acetate in men with castration-resistant prostate cancer. Prostate Cancer Prostatic Dis. 2016 12; 19(4):398-405.
View in: PubMed

Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer. N Engl J Med. 2016 Aug 04; 375(5):443-53.
View in: PubMed

Association of tumour microRNA profiling with outcomes in patients with advanced urothelial carcinoma receiving first-line platinum-based chemotherapy. Br J Cancer. 2016 06 28; 115(1):12-9.
View in: PubMed

Redirecting abiraterone metabolism to fine-tune prostate cancer anti-androgen therapy. Nature. 2016 05 26; 533(7604):547-51.
View in: PubMed

A Randomized Phase II Trial of Short-Course Androgen Deprivation Therapy With or Without Bevacizumab for Patients With Recurrent Prostate Cancer After Definitive Local Therapy. J Clin Oncol. 2016 06 01; 34(16):1913-20.
View in: PubMed

ErbB2 Signaling Increases Androgen Receptor Expression in Abiraterone-Resistant Prostate Cancer. Clin Cancer Res. 2016 07 15; 22(14):3672-82.
View in: PubMed

Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3. J Clin Oncol. 2016 Apr 20; 34(12):1402-18.
View in: PubMed

Duration of Androgen Deprivation Therapy for High-Risk Prostate Cancer: Application of Randomized Trial Data in a Tertiary Referral Cancer Center. Clin Genitourin Cancer. 2016 08; 14(4):e299-305.
View in: PubMed

Genetic Effect of Chemotherapy Exposure in Children of Testicular Cancer Survivors. Clin Cancer Res. 2016 05 01; 22(9):2183-9.
View in: PubMed

Androgen Receptor Modulation Optimized for Response (ARMOR) Phase I and II Studies: Galeterone for the Treatment of Castration-Resistant Prostate Cancer. Clin Cancer Res. 2016 Mar 15; 22(6):1356-63.
View in: PubMed

Prior Endocrine Therapy Impact on Abiraterone Acetate Clinical Efficacy in Metastatic Castration-resistant Prostate Cancer: Post-hoc Analysis of Randomised Phase 3 Studies. Eur Urol. 2016 05; 69(5):924-32.
View in: PubMed

A Molecular Model for Predicting Overall Survival in Patients with Metastatic Clear Cell Renal Carcinoma: Results from CALGB 90206 (Alliance). EBioMedicine. 2015 Nov; 2(11):1814-20.
View in: PubMed

Has the Time Arrived for Biomarker-Directed Therapy in Castration-Resistant Prostate Cancer? JAMA Oncol. 2015 Aug; 1(5):577-9.
View in: PubMed

Integrative Clinical Genomics of Advanced Prostate Cancer. Cell. 2015 Jul 16; 162(2):454.
View in: PubMed

Detecting metastatic prostate carcinoma in pelvic lymph nodes following neoadjuvant hormone therapy: the eyes have it! Histopathology. 2016 Jan; 68(2):303-7.
View in: PubMed

Somatic Copy Number Abnormalities and Mutations in PI3K/AKT/mTOR Pathway Have Prognostic Significance for Overall Survival in Platinum Treated Locally Advanced or Metastatic Urothelial Tumors. PLoS One. 2015; 10(6):e0124711.
View in: PubMed

Integrative clinical genomics of advanced prostate cancer. Cell. 2015 May 21; 161(5):1215-1228.
View in: PubMed

Docetaxel, bevacizumab, and androgen deprivation therapy for biochemical disease recurrence after definitive local therapy for prostate cancer. Cancer. 2015 Aug 01; 121(15):2603-11.
View in: PubMed

Long-term Safety and Antitumor Activity in the Phase 1-2 Study of Enzalutamide in Pre- and Post-docetaxel Castration-Resistant Prostate Cancer. Eur Urol. 2015 Nov; 68(5):795-801.
View in: PubMed

Castration-resistant prostate cancer bone metastasis response measured by 18F-fluoride PET after treatment with dasatinib and correlation with progression-free survival: results from American College of Radiology Imaging Network 6687. J Nucl Med. 2015 Mar; 56(3):354-60.
View in: PubMed

Association of PD-L1 expression on tumor-infiltrating mononuclear cells and overall survival in patients with urothelial carcinoma. Ann Oncol. 2015 Apr; 26(4):812-817.
View in: PubMed

Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2015 Feb; 16(2):152-60.
View in: PubMed

Treatment With Galeterone in an Elderly Man With Castration-Resistant Prostate Cancer: A Case Report. Clin Genitourin Cancer. 2015 Aug; 13(4):e325-e328.
View in: PubMed

(18)F-FDG-PET/CT and (18)F-NaF-PET/CT in men with castrate-resistant prostate cancer. Am J Nucl Med Mol Imaging. 2015; 5(1):72-82.
View in: PubMed

The DHEA-sulfate depot following P450c17 inhibition supports the case for AKR1C3 inhibition in high risk localized and advanced castration resistant prostate cancer. Chem Biol Interact. 2015 Jun 05; 234:332-8.
View in: PubMed

Intermittent Chemotherapy as a Platform for Testing Novel Agents in Patients With Metastatic Castration-Resistant Prostate Cancer: A Department of Defense Prostate Cancer Clinical Trials Consortium Randomized Phase II Trial of Intermittent Docetaxel With Prednisone With or Without Maintenance GM-CSF. Clin Genitourin Cancer. 2015 Jun; 13(3):e191-8.
View in: PubMed

A phase I study of everolimus and docetaxel in patients with castration-resistant prostate cancer. Clin Genitourin Cancer. 2015 Apr; 13(2):113-23.
View in: PubMed

Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors. Clin Cancer Res. 2015 Mar 15; 21(6):1273-80.
View in: PubMed

Intense androgen-deprivation therapy with abiraterone acetate plus leuprolide acetate in patients with localized high-risk prostate cancer: results of a randomized phase II neoadjuvant study. J Clin Oncol. 2014 Nov 20; 32(33):3705-15.
View in: PubMed

Systemic therapy in men with metastatic castration-resistant prostate cancer:American Society of Clinical Oncology and Cancer Care Ontario clinical practice guideline. J Clin Oncol. 2014 Oct 20; 32(30):3436-48.
View in: PubMed

Imaging, procedural and clinical variables associated with tumor yield on bone biopsy in metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis. 2014 Dec; 17(4):325-31.
View in: PubMed

Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014 Jul 31; 371(5):424-33.
View in: PubMed

Neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with pegfilgrastim support in muscle-invasive urothelial cancer: pathologic, radiologic, and biomarker correlates. J Clin Oncol. 2014 Jun 20; 32(18):1889-94.
View in: PubMed

Whole-exome sequencing of circulating tumor cells provides a window into metastatic prostate cancer. Nat Biotechnol. 2014 May; 32(5):479-84.
View in: PubMed

Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib. Cancer Discov. 2014 May; 4(5):546-53.
View in: PubMed

Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302). Eur Urol. 2014 Nov; 66(5):815-25.
View in: PubMed

Functional analysis of single cells identifies a rare subset of circulating tumor cells with malignant traits. Integr Biol (Camb). 2014 Apr; 6(4):388-98.
View in: PubMed

Dynamic contrast-enhanced magnetic resonance imaging in prostate cancer clinical trials: potential roles and possible pitfalls. Transl Oncol. 2014 Feb; 7(1):120-9.
View in: PubMed

Enzalutamide for the treatment of prostate cancer: results and implications of the AFFIRM trial. Future Oncol. 2014 Feb; 10(3):351-62.
View in: PubMed

Targeted androgen pathway suppression in localized prostate cancer: a pilot study. J Clin Oncol. 2014 Jan 20; 32(3):229-37.
View in: PubMed

A urologic oncology roundtable discussion: issues to consider in choosing treatment for metastatic castration-resistant prostate cancer. Hosp Pract (1995). 2013 Oct-Nov; 41(4):81-2.
View in: PubMed

Optimizing bone health and minimizing skeletal morbidity in men with prostate cancer. Hematol Oncol Clin North Am. 2013 Dec; 27(6):1261-83, ix.
View in: PubMed

Rationale for and review of neoadjuvant therapy prior to radical prostatectomy for patients with high-risk prostate cancer. Drugs. 2013 Sep; 73(13):1417-30.
View in: PubMed

Abiraterone acetate: targeting persistent androgen dependence in castration-resistant prostate cancer. Adv Ther. 2013 Aug; 30(8):727-47.
View in: PubMed

Development, validation and application of a stable isotope dilution liquid chromatography electrospray ionization/selected reaction monitoring/mass spectrometry (SID-LC/ESI/SRM/MS) method for quantification of keto-androgens in human serum. J Steroid Biochem Mol Biol. 2013 Nov; 138:281-9.
View in: PubMed

Clinical predictors of survival in men with castration-resistant prostate cancer: evidence that Gleason score 6 cancer can evolve to lethal disease. Cancer. 2013 Aug 15; 119(16):2990-8.
View in: PubMed

Secondary hormone therapy for castration-resistant prostate cancer. Oncology (Williston Park). 2013 May; 27(5):371-2.
View in: PubMed

Long-term follow-up of a phase II trial of chemotherapy plus hormone therapy for biochemical relapse after definitive local therapy for prostate cancer. Urology. 2013 Mar; 81(3):611-6.
View in: PubMed

Long-term responders to enzalutamide (ENZA) during the phase III AFFIRM trial: Baseline characteristics and efficacy outcomes. J Clin Oncol. 2013 Feb 20; 31(6_suppl):20.
View in: PubMed

Impact of on-study corticosteroid use on efficacy and safety in the phase III AFFIRM study of enzalutamide (ENZA), an androgen receptor inhibitor. J Clin Oncol. 2013 Feb 20; 31(6_suppl):6.
View in: PubMed

Paradoxical significance of endorectal MRI (erMRI) response to neoadjuvant chemotherapy in patients with high-risk localized prostate cancer (HRLPC). J Clin Oncol. 2013 Feb 20; 31(6_suppl):23.
View in: PubMed

A phase II multicenter study of neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (ddMVAC) chemotherapy with pegfilgrastim support in patients (pts) muscle-invasive urothelial cancer (MIUC): Safety, pathologic, radiologic, and molecular correlates. J Clin Oncol. 2013 Feb 20; 31(6_suppl):278.
View in: PubMed

Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 2013 Jan 10; 368(2):138-48.
View in: PubMed

Phase II trial of RAD001 and bicalutamide for castration-resistant prostate cancer. BJU Int. 2012 Dec; 110(11):1729-35.
View in: PubMed

Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012 Sep 27; 367(13):1187-97.
View in: PubMed

Atypical metastases from prostate cancer: 10-year experience at a single institution. AJR Am J Roentgenol. 2012 Aug; 199(2):367-72.
View in: PubMed

The evolving paradigm of second-line hormonal therapy options for castration-resistant prostate cancer. Curr Opin Oncol. 2012 May; 24(3):272-7.
View in: PubMed

Effect of MDV3100, an androgen receptor signaling inhibitor (ARSI), on overall survival in patients with prostate cancer postdocetaxel: Results from the phase III AFFIRM study. J Clin Oncol. 2012 Feb 10; 30(5_suppl):LBA1.
View in: PubMed

Phase 2 study of neoadjuvant docetaxel plus bevacizumab in patients with high-risk localized prostate cancer: a Prostate Cancer Clinical Trials Consortium trial. Cancer. 2012 Oct 01; 118(19):4777-84.
View in: PubMed

Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer. J Clin Oncol. 2012 Feb 10; 30(5):507-12.
View in: PubMed

Secondary hormonal therapy in men with castration-resistant prostate cancer. Clin Genitourin Cancer. 2011 Dec; 9(2):95-103.
View in: PubMed

Case report: responses to cabazitaxel in metastatic castration-resistant prostate cancer after extensive docetaxel treatment. Clin Genitourin Cancer. 2011 Dec; 9(2):130-2.
View in: PubMed

Phase II study of abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer displaying bone flare discordant with serologic response. Clin Cancer Res. 2011 Jul 15; 17(14):4854-61.
View in: PubMed

SLCO2B1 and SLCO1B3 may determine time to progression for patients receiving androgen deprivation therapy for prostate cancer. J Clin Oncol. 2011 Jun 20; 29(18):2565-73.
View in: PubMed

A phase II study of neoadjuvant docetaxel (D) plus bevacizumab (B) in patients (pts) with high-risk localized prostate cancer. J Clin Oncol. 2011 May 20; 29(15_suppl):4642.
View in: PubMed

Follow-up study of chemotherapy plus hormone therapy for biochemical relapse after definitive local therapy for prostate cancer. J Clin Oncol. 2011 May 20; 29(15_suppl):4657.
View in: PubMed

Novel agents and new therapeutics in castration-resistant prostate cancer. Curr Opin Oncol. 2011 May; 23(3):290-6.
View in: PubMed

Urothelial cancers of the upper urinary tract: metastatic pattern and its correlation with tumor histopathology and location. J Comput Assist Tomogr. 2011 Mar-Apr; 35(2):217-22.
View in: PubMed

Metastatic pattern of bladder cancer: correlation with the characteristics of the primary tumor. AJR Am J Roentgenol. 2011 Jan; 196(1):117-22.
View in: PubMed

Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet. 2010 Apr 24; 375(9724):1437-46.
View in: PubMed

Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer. J Clin Oncol. 2010 Mar 20; 28(9):1496-501.
View in: PubMed

Phase II study of androgen synthesis inhibition with ketoconazole, hydrocortisone, and dutasteride in asymptomatic castration-resistant prostate cancer. Clin Cancer Res. 2009 Nov 15; 15(22):7099-105.
View in: PubMed

Activity of ketoconazole after taxane-based chemotherapy in castration-resistant prostate cancer. BJU Int. 2010 May; 105(10):1392-6.
View in: PubMed

Activity of dutasteride plus ketoconazole in castration-refractory prostate cancer after progression on ketoconazole alone. Clin Genitourin Cancer. 2009 Oct; 7(3):E90-2.
View in: PubMed

Phase II multicenter study of chemotherapy (chemo)-naive castration-resistant prostate cancer (CRPC) not exposed to ketoconazole (keto), treated with abiraterone acetate (AA) plus prednisone. J Clin Oncol. 2009 May 20; 27(15_suppl):5046.
View in: PubMed

A phase II study of neoadjuvant chemotherapy with docetaxel and bevacizumab in patients (pts) with high-risk localized prostate cancer: A Prostate Cancer Clinical Trials Consortium trial. J Clin Oncol. 2009 May 20; 27(15_suppl):5060.
View in: PubMed

Antitumor activity of MDV3100 in a phase I/II study of castration-resistant prostate cancer (CRPC). J Clin Oncol. 2009 May 20; 27(15_suppl):5011.
View in: PubMed

Phase II multicenter study of abiraterone acetate (AA) plus prednisone therapy in docetaxel-treated castration-resistant prostate cancer (CRPC) patients (pts): Impact of prior ketoconazole (keto). J Clin Oncol. 2009 May 20; 27(15_suppl):5048.
View in: PubMed

Time to prostate-specific antigen nadir independently predicts overall survival in patients who have metastatic hormone-sensitive prostate cancer treated with androgen-deprivation therapy. Cancer. 2009 Mar 01; 115(5):981-7.
View in: PubMed

Androgen receptor: role and novel therapeutic prospects in prostate cancer. Expert Rev Anticancer Ther. 2008 Sep; 8(9):1495-508.
View in: PubMed

Phase I trial of RAD001 (R) and docetaxel (D) in castration resistant prostate cancer (CRPC) with FDG-PET assessment of RAD001 activity. J Clin Oncol. 2008 May 20; 26(15_suppl):5069.
View in: PubMed

Impact of prior ketoconazole therapy on response proportion to abiraterone acetate, a 17-alpha hydroxylase C17,20-lyase inhibitor in castration resistant prostate cancer (CRPC). J Clin Oncol. 2008 May 20; 26(15_suppl):5018.
View in: PubMed

Phase II trial of ketoconazole, hydrocortisone, and dutasteride (KHAD) for castration resistant prostate cancer (CRPC). J Clin Oncol. 2008 May 20; 26(15_suppl):5068.
View in: PubMed

A phase II study of mifepristone (RU-486) in castration-resistant prostate cancer, with a correlative assessment of androgen-related hormones. BJU Int. 2008 May; 101(9):1084-9.
View in: PubMed

A Phase II Study of Mifepristone (RU-486) in Castration Resistant Prostate Cancer with Correlative Assessment of Androgen related hormones. BJU. 2008; 101:1084-89.

Efficacy of androgen deprivation therapy (ADT) in patients with advanced prostate cancer: association between Gleason score, prostate-specific antigen level, and prior ADT exposure with duration of ADT effect. Cancer. 2008 Mar 15; 112(6):1247-53.
View in: PubMed

Inherited variation in the androgen pathway is associated with the efficacy of androgen-deprivation therapy in men with prostate cancer. J Clin Oncol. 2008 Feb 20; 26(6):842-7.
View in: PubMed

Response to docetaxel/carboplatin-based chemotherapy as first- and second-line therapy in patients with metastatic hormone-refractory prostate cancer. BJU Int. 2008 Feb; 101(3):308-12.
View in: PubMed

A phase 2 study of carboplatin plus docetaxel in men with metastatic hormone-refractory prostate cancer who are refractory to docetaxel. Cancer. 2008 Feb 01; 112(3):521-6.
View in: PubMed

Phase II trial of ketoconazole, hydrocortisone and dutastride (KHAD) for castration resistant prostate cancer (CRPC) with correlative assessment of adrenal androgen levels. Proc Am Soc Clin Onc. 2008; 26(2008):abst 5062.

Phase I trial of RAD001 (R) and docetaxeol (D) in castration resistant prostate cancer (CRPC) with PET assessment of RAD001 activity. Proc Am Soc Clin Onc. 2008; 26(May 20):abstr 5069.

Impact of prior ketoconazole therapy on response proportion to abiraterone acetate, a 17-alpha hydroxylase C17,20-lyase inhibitor in castration resistant prostate cancer (CRPC). J Clin Oncol. 2008; 26(May 20):abstr 5018.

Phase I trial of RAD001 (R) and docetaxel (D) in castration resistant prostate cancer (CRPC) with FDG-PET assessment of RAD001 activity. J Clin Oncol. 2008; 26(May 20):abstr 5069.

Tumor volume changes on 1.5 tesla endorectal MRI during neoadjuvant hormonal therapy for higher-risk prostate cancer and recurrence in men managed using radiation therapy: Results of CALGB 9682. Int J Radiat Oncol Biol Phys . 2008.

Phase II trial of ketoconazole, hydrocortisone, and dutasteride (KHAD) for castration resistant prostate cancer (CRPC). J Clin Oncol. 2008; 26(May 20):abstr 5068.

Osteporosis and Bone Fracture: Evaluation. 2007.

Phase II study of low dose and high dose conjugated estrogen for androgen independent prostate cancer. J Urol. 2007 Jun; 177(6):2146-50.
View in: PubMed

Phase II study of low dose and high dose premarin in androgen independent prostate cancer. J Urol. 2007; 177(6):2146-50.

Initial Hormonal Management of Androgen-Sensitive Metastatic, Recurrent, or Progressive Prostate Cancer --2006 Update of an American Society of Clinical Oncology Practice Guideline . J Clin Oncol. 2007; 25(12):1596-605.

Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol. 2007 Apr 20; 25(12):1596-605.
View in: PubMed

Drug insight: role of the androgen receptor in the development and progression of prostate cancer. Nat Clin Pract Oncol. 2007 Apr; 4(4):236-44.
View in: PubMed

Activity of dustasteride plus ketoconazole in hormone-refractory prostate cancer (HRPC) after progression on ketoconzole alone. Proc Am Soc Clin Onc. 2007.

A phase II trial of docetaxel plus carboplatin in hormone refractory prostate cancer (HRPC) patients who have progressed after prior docetaxel chemotherapy. Proc Am Soc Clin Onc. 2007.

Case report and review: a patient with rising PSA after radical prostatectomy treated with docetaxel, estramustine, and 15 months of androgen deprivation - 7-Year Remission. Am J Hematol Oncol. 2007; 6(4 ):1-3.

Phase II study of trilostane and hydrocortisone for androgen-independent prostate cancer. Proc Am Soc Clin Onc. 2007.

Docetaxel, estramustine, and 15-month androgen deprivation for men with prostate-specific antigen progression after definitive local therapy for prostate cancer. J Clin Oncol. 2006 Dec 01; 24(34):5408-13.
View in: PubMed

Mifepristone (RU-486) in androgen independent prostate cancer. J Clin Oncol. 2006 Jun 20; 24(18_suppl):14508.
View in: PubMed

Chemo-hormonal therapy for biochemical progression of prostate cancer. J Clin Oncol. 2006 Jun 20; 24(18_suppl):4559.
View in: PubMed

Phase II study of low dose (LD) and high dose (HD) premarin in androgen independent prostate cancer (AIPC). J Clin Oncol. 2006 Jun 20; 24(18_suppl):4560.
View in: PubMed

Quality of life and pain in advanced stage prostate cancer: results of a Southwest Oncology Group randomized trial comparing docetaxel and estramustine to mitoxantrone and prednisone. J Clin Oncol. 2006 Jun 20; 24(18):2828-35.
View in: PubMed

Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16. J Natl Cancer Inst. 2006 Apr 19; 98(8):516-21.
View in: PubMed

Prostate Cancer Update: Conversations with urologic oncology leaders bridging the gap between research and patient care. 2006.

Predictors of prostate cancer tissue acquisition by an undirected core bone marrow biopsy in metastatic castration-resistant prostate cancer--a Cancer and Leukemia Group B study. Clin Cancer Res. 2005 Nov 15; 11(22):8109-13.
View in: PubMed

Efficacy of nilutamide as secondary hormonal therapy in androgen-independent prostate cancer. BJU Int. 2005 Oct; 96(6):783-6.
View in: PubMed

Prognostic significance of plasma chromogranin a levels in patients with hormone-refractory prostate cancer treated in Cancer and Leukemia Group B 9480 study. Urology. 2005 Aug; 66(2):386-91.
View in: PubMed

Phase II study of three hour, weekly infusion of trabectedin (ET-743) in men with metastatic, androgen-independent prostate carcinoma (AIPC). J Clin Oncol. 2005 Jun; 23(16_suppl):4517.
View in: PubMed

Efficacy of nilutamide as secondary hormonal therapy in androgen-independent prostate cancer (AIPC). (abstract). Proc Am Soc Clin Onc. 2005.

Phase II study of three hour, weekly infusion of trabectedin (ET-743) in men with metastatic, androgen-independent prostate carcinoma (AIPC). (abstract). Proc Am Soc Clin Onc. 2005.

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004 Oct 07; 351(15):1513-20.
View in: PubMed

Quality of life (QOL) and pain in advanced stage prostate cancer: impact of missing data on evaluating palliation in SWOG 9916. J Clin Oncol. 2004 Jul 15; 22(14_suppl):4579.
View in: PubMed

Prognostic significance of plasma chromogranin A levels in hormone-refractory prostate cancer patients treated on Cancer and Leukemia Group B (CALGB) 9480. J Clin Oncol. 2004 Jul 15; 22(14_suppl):4557.
View in: PubMed

Docetaxel plus carboplatin (DC) may have significant activity in hormone refractory prostate cancer (HRPC) patients who have progressed after prior docetaxel-based chemotherapy. J Clin Oncol. 2004 Jul 15; 22(14_suppl):4679.
View in: PubMed

Three-month change in PSA as a surrogate endpoint for mortality in advanced hormone-refractory prostate cancer (HRPC): Data from Southwest Oncology Group Study S9916. J Clin Oncol. 2004 Jul 15; 22(14_suppl):4505.
View in: PubMed

Monitoring the serological proteome: the latest modality in prostate cancer detection. J Urol. 2004 Jul; 172(1):331-7.
View in: PubMed

American Society of Clinical Oncology recommendations for the initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer. J Clin Oncol. 2004 Jul 15; 22(14):2927-41.
View in: PubMed

Androgen receptor: a key molecule in the progression of prostate cancer to hormone independence. J Cell Biochem. 2004 Feb 15; 91(3):483-90.
View in: PubMed

Special Report: evolving role of chemotherapy in the management of prostate cancer. 2004.

Prognostic significance of plasma chromogranin A levels in hormone-refractory prostate cancer patients treated on cancer and leukemia group B (CALGB) 9480. Proc Am Soc Clin Onc. 2004.

Quality of life (QOL) and pain in advanced prostate cancer: impact of missing data on evaluating palliation in SWOG 9916. POSTER DISCUSSION. Proc Am Soc Clin Onc. 2004.

Chapter 3: External Beam Radiotherapy, Radiopharmaceuticals, and Chemotherapy for Hormone-Refactory Prostate Cancer. In: Management of Skeletal Complications of Prostate Cancer and Other Genitourinary Malignancies. Kantoff PW, Saad F, Smith MR. 2004; 87-151.

Acute renal failure after intravenous anti-D immune globulin in an adult with immune thrombocytopenic purpura. Am J Hematol. 2003 Dec; 74(4):276-9.
View in: PubMed

The ingredients for prostate cancer nomograms: the addition of biomarkers sets the table for future recipes. J Clin Oncol. 2003 Oct 01; 21(19):3552-3.
View in: PubMed

Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663. J Clin Oncol. 2003 Jul 15; 21(14):2673-8.
View in: PubMed

Biochemical (Prostate-Specific Antigen) Relapse: An Oncologist's Perspective. Rev Urol. 2003; 5 Suppl 3:S3-S13.
View in: PubMed

Biochemical (Prostate-Specific Antigen) Relapse: An Oncologist's Perspective. Rev Urol. 2003; 5 Suppl 2:S3-S13.
View in: PubMed

Critical evaluation of hormone therapy for carcinoma of the prostate. Urology. 2002; 60:201-208.

Docetaxel (D), estramustine (E) and short-term androgen withdrawal for patients with a rising PSA after definitive local therapy of prostate cancer. Proc Am Soc Clin Onc. 2002.

Lack of effect of aminoglutethimide and hydrocortisone added to high-dose bicalutamide for androgen independent prostate cancer. The Prostate J. 2002; 3:1-7.

Clinical review 134: The endocrinology of prostate cancer. J Clin Endocrinol Metab. 2001 Aug; 86(8):3467-77.
View in: PubMed

Docetaxel, estramustine, and short-term androgen withdrawal for patients with biochemical failure after definitive local therapy for prostate cancer. Semin Oncol. 2001 Aug; 28(4 Suppl 15):32-9.
View in: PubMed

Comparative studies of the estrogen receptors beta and alpha and the androgen receptor in normal human prostate glands, dysplasia, and in primary and metastatic carcinoma. Am J Pathol. 2001 Jul; 159(1):79-92.
View in: PubMed

Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: a final report of CALGB 9780. Cancer and Leukemia Group B. J Clin Oncol. 2001 May 01; 19(9):2509-16.
View in: PubMed

Androgen receptor mutations in androgen independent prostate cancer (AiPCa) do not correlate with the anti-androgen withdrawal response: Cancer and Leukemia Group B (CALGB) 9663. Proc Am Soc Clin Onc. 2001.

Androgen receptor mutations in advanced prostate cancer: preliminary results of CALGB 9663. Proc Am Soc Clin Onc. 2000; 19:1297.

Physiology and endocrinology of the prostate. In: Vogelzang NJ, Scardino PT, Shipley WU, Coffey DS, eds. Comprehensive Textbook of Genitourinary Oncology. 2000.

A phase II study of docetaxel (Taxotere), estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: preliminary results of cancer and leukemia group B Trial 9780. Semin Oncol. 1999 Oct; 26(5 Suppl 17):39-44.
View in: PubMed

Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist. Cancer Res. 1999 Jun 01; 59(11):2511-5.
View in: PubMed

A Phase II Study of docetaxel, estramustine and low dose hydrocortisone in hormone refractory prostate cancer. Proc Am Soc Clin Onc. 1999; 18:295.

A Phase II Study of docetaxel, estramustine and low dose hydrocortisone in men with hormone refractory prostate cancer: preliminary results of CALGB 9780. Proc AUA. 1999.

Novel therapeutic strategies in prostate cancer. In: D'Amico A, Hanks G, eds. Radiotherapeutic Management of Carcinoma of the Prostate. 1999.

High dose bicalutamide for androgen independent prostate cancer: effect of prior hormonal therapy. J Urol. 1998 Jan; 159(1):149-53.
View in: PubMed

Androgen receptor mutations from androgen independent prostate cancer are associated with previous hydroxyflutamide treatment. Keystone Symposium. 1998; 318.

GM-CSF Priming with successive concomitant therapy with low-dose ARA-C for older patients with advanced myelodysplastic syndrome (MDS), secondary or refractory acute myeloid leukemia (AML). Am Society of Hematology. 1998.

Functional characterization of mutant androgen receptors from androgen-independent prostate cancer. Clin Cancer Res. 1997 Aug; 3(8):1383-8.
View in: PubMed

Evidence against T-cell development in the adult human intestinal mucosa based upon lack of terminal deoxynucleotidyltransferase expression. Immunology. 1996 Mar; 87(3):402-7.
View in: PubMed

Functional analysis of mutant androgen receptor from androgen independent prostate cancer keystone symposia: breast and prostate cancer: Basic Mechanisms. 1996.

Bicalutamide for androgen-independent prostate cancer. Proc Am Soc Clin Onc. 1996; 14:262.

Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N Engl J Med. 1995 May 25; 332(21):1393-8.
View in: PubMed

Androgen receptor mutations in human hormone-independent prostate cancer. Proc Am Cancer Res. 1994; 35:273.

Androgen receptor mutations in human hormone-independent prostate cancer. J. Cellular Biochemistry. 1994; 239.

Repeated intensive cyclophosphamide, doxorubicin and VP-16 with recombinant human granulocyte-macrophage colony stimulating factor (rhGM-CSF). Proc Am Soc Clin Onc. 1992; 11:1414.

Poisoning by salicylates and other nonsteroidal anti-inflammatory drugs. In: Rippe JM, Irwin RS, Alpert JS, Fink M, eds. Intensive Care Medicine. 1991.

Presumptive evidence for Blastocystis hominis as a cause of colitis. Arch Intern Med. 1988 May; 148(5):1064.
View in: PubMed

Vitamin B12 levels and age. Am J Clin Pathol. 1986 Jan; 85(1):32-6.
View in: PubMed

Location

Dana-Farber Cancer Institute
450 Brookline Avenue
Dana 1232C
Boston, MA 02215
Get Directions

Ratings

Top